Market cap
₹12 Cr
Recently Viewed
Clear AllBSE: 531210
₹46.10
₹-1.74
(-3.64%)
As on 30-Apr-2026IST
Market cap
₹12 Cr
Revenue (TTM)
₹6 Cr
P/E Ratio
22.6
P/B Ratio
1.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹1 Cr
ROE
5.4 %
ROCE
6.7 %
Industry P/E
45.72
EV/EBITDA
3.9
Debt to Equity
0
Book Value
₹39.9
EPS
₹2
Face value
10
Shares outstanding
2,519,100
CFO
₹4.28 Cr
EBITDA
₹4.44 Cr
Net Profit
₹2.71 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Colinz Lab
| -14.0 | 6.0 | -42.3 | -15.1 | 3.4 | 31.4 | 12.6 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Colinz Lab
| -25.0 | 74.4 | -7.0 | 55.5 | 96.1 | 42.7 | 7.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Colinz Lab
|
46.1 | 11.6 | 6.1 | 0.5 | 4.1 | 5.1 | 22.6 | 1.2 |
| 2,594.1 | 21,258.3 | 1,339.4 | 356.4 | 33.2 | 23.2 | 59.7 | 14.0 | |
| 699.7 | 17,327.2 | 5,365.6 | 595.0 | 16.6 | 13.3 | 29.1 | 3.4 | |
| 1,101.0 | 59,335.6 | 6,812.9 | 889.9 | 19.0 | 17.6 | 66.8 | 11.7 | |
| 161.9 | 21,520.5 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.6 | |
| 467.7 | 18,887.7 | 3,738.7 | 316.7 | 12.5 | 7.5 | 59.6 | 3.9 |
No Review & Analysis are available.
Colinz Laboratories Limited manufactures and markets pharmaceutical formulations in India It provides pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, etc.; and specialized... products for gynecology, cardiology, gastroenterology, etc. The company's allopathy products include oncology products and antiritrovirals; and products for other therapeutic areas, such as antibiotics, anti-pyretics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anti-diarrhoeals, anti-inflammatory, anti-piles, anthelmintics, anti-emetics, anti-spasmodics, infestations, sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormone, sunscreens and vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. It also provides ayurvedic products, including anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, apetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, ear drops, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction. In addition, the company offers nutraceuticals that include spirulina tabs/caps; spirulina with vitamins and minerals; omega 3 fatty acids caps in softgel; codliver oil with vitamin caps in soft gel; collagen, glucosamine, and chondroitin tabs; amino acids tabs/caps; L-arginine with proantocyanidin granules; and hair growth formulas, etc. The company was founded in 1986 and is based in Mumbai, India. Read more
Incorporated
1986
Chairman
--
Managing Director
--
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Colinz Laboratories Ltd is ₹46.10 (BSE) as of 30-Apr-2026 IST. Colinz Laboratories Ltd has given a return of 3.35% in the last 3 years.
The P/E ratio of Colinz Laboratories Ltd is 22.64 times as on 30-Apr-2026, a 50 discount to its peers’ median range of 45.72 times.
The P/B ratio of Colinz Laboratories Ltd is 1.16 times as on 30-Apr-2026, a 68 discount to its peers’ median range of 3.67 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
36.75
|
1.93
|
|
2024
|
19.44
|
1.06
|
|
2023
|
19.28
|
1.08
|
|
2022
|
24.60
|
1.09
|
|
2021
|
12.98
|
0.37
|
The 52-week high and low of Colinz Laboratories Ltd are Rs 87.91 and Rs 36.11 as of 01-May-2026.
Colinz Laboratories Ltd has a market capitalisation of ₹ 12 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Colinz Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.